Clinical trial
Efficacy, Safety, and Cost-Effectiveness of Albumin-Bound Paclitaxel (Ⅱ) in Chinese Patients With Advanced Breast Cancer: A Multicenter, Observational, Real-World Study
NCT07899047 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety, and Cost-Effectiveness of Albumin-Bound Paclitaxel (Ⅱ) in Chinese Patients With Advanced Breast Cancer: A Multicenter, Observational, Real-World Study
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- May 31, 2030
- Enrollment
- 1,372 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced breast cancer, breast cancer, her2-negative breast cancer
Arms
As registered; 2 arms.
-
Experimental Group
-
Control group
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Overall Survival (OS)
Time from the participant's first study-drug administration to death from any cause.
Lead sponsor's other trials
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, most recent start first.
+405 more trials
Similar trials
Same condition (Breast Neoplasms) and phase, most recent start first.
+3,018 more trials See the condition page